Manning Paul B

Average Profitability
<0.0001%
Insider Buys Quantity
34
Insider Buys Sum
$84.39M
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of Manning Paul B

According to the SEC Form 4 filings, Manning Paul B, being in a position of

  1. director at Liquidia Corporation,
    оver the last 12 months, has bought 616408 shares for $5M, and sold 0 shares,
    over all time since 2021-04-13, has bought 1405390 shares for $8M, and sold 0 shares.

The largest purchase of all time was on 2023-08-16 and amounted to 16466667 shares of Taysha Gene Therapies, Inc. for $14.82M.

Biography of Manning Paul B

No biography is available at this moment.

2024-09-12PurchaseLiquidia Corporation
LQDA
director
337,078
0.4019%
$8.90$3M+11.63%
2024-06-27PurchaseTaysha Gene Therapies, Inc.
TSHA
10 percent owner
1.33M
0.7863%
$2.25$3M0%
2023-12-14PurchaseLiquidia Corporation
LQDA
director
279,330
0.4244%
$7.16$2M+72.31%
2023-11-17PurchaseTaysha Gene Therapies, Inc.
TSHA
10 percent owner
100,000
0.0519%
$1.63$163,000+29.34%
2023-08-16PurchaseTaysha Gene Therapies, Inc.
TSHA
10 percent owner
16.47M
11.9647%
$0.90$14.82M+21.5%
2023-07-24PurchaseVerrica Pharmaceuticals Inc.
VRCA
200,000
0.4567%
$5.02$1M+4.11%
2022-10-31PurchaseTaysha Gene Therapies, Inc.
TSHA
director
1.5M
3.9684%
$2.00$3M-34.88%
2022-07-05PurchaseVerrica Pharmaceuticals Inc.
VRCA
4.76M
9.9243%
$2.10$10M+61.6%
2022-04-18PurchaseLiquidia Corporation
LQDA
392,156
0.6258%
$5.10$2M+9.53%
2022-02-03PurchaseTaysha Gene Therapies, Inc.
TSHA
76,602
0.2022%
$7.84$600,560-59%
2022-02-02PurchaseTaysha Gene Therapies, Inc.
TSHA
125,000
0.3321%
$7.77$971,250-57.83%
2021-12-03PurchaseVerrica Pharmaceuticals Inc.
VRCA
19,977
0.0723%
$9.22$184,188-57.78%
2021-12-02PurchaseVerrica Pharmaceuticals Inc.
VRCA
30,023
0.1097%
$9.45$283,717-58.35%
2021-11-24PurchaseTaysha Gene Therapies, Inc.
TSHA
2,202
0.0057%
$13.19$29,044-68.09%
2021-11-23PurchaseTaysha Gene Therapies, Inc.
TSHA
20,000
0.0513%
$12.54$250,800-66.71%
2021-07-29PurchaseCandel Therapeutics, Inc.
CADL
1.63M
7.6346%
$8.00$13M-24.18%
2021-07-27PurchaseCandel Therapeutics, Inc.
CADL
director
36,000
0.1622%
$7.36$264,834-18.36%
2021-07-06PurchaseAcumen Pharmaceuticals, Inc.
ABOS
10 percent owner
312,500
0.6468%
$16.00$5M-67.95%
2021-05-14PurchaseTaysha Gene Therapies, Inc.
TSHA
12,000
0.0321%
$20.98$251,760-28.44%
2021-04-13PurchaseLiquidia Corporation
LQDA
396,826
0.7682%
$2.52$1M+23.24%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.